Skip to content

Study · Not a test of the peptide alone · 2024

6 results

Sex, race, and BMI in clinical trials of medications for obesity over the past three decades: a systematic review.

Alsaqaaby MS, Cooney S, le Roux CW, Pournaras DJ

The lancet. Diabetes & endocrinology6 May 2024Cited by 30 (Europe PMC)

PMID38723646 (opens in a new tab)DOI10.1016/s2213-8587(24)00098-6 (opens in a new tab)PepBankPUB-38723646
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Orforglipron aloneSystematic reviewOther

    Across obesity medication trials including orforglipron, most trials over-recruited female participants and under-recruited male participants.

    In plain wordsAcross obesity medication trials including orforglipron, most trials over-recruited female participants and under-recruited male participants.

    Peptide
    Orforglipron
    Outcome
    MixedSex representation
    Study

    n = 139,566

    Outcome group
    Patterns of use · Whole body

    Source sentences

    Summary
    Most trials over-recruited White, female participants aged 40 years or older with class 1 (30·0-34·9 kg/m2) and class 2 (35·0-39·9 kg/m2) obesity;
    2 context sentences
    Summary · context
    older participants, those with class 3 (≥40·0 kg/m2) obesity, non-White participants, and male participants were under-recruited.
    Summary · context
    246 RCTs were included, involving 139 566 participants with or without type 2 diabetes.

    In this study, Orforglipron was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Orforglipron.

  2. 02HumanNot a test of Orforglipron aloneSystematic reviewOther

    Across obesity medication trials including orforglipron, most trials over-recruited participants aged 40 years or older, while older participants were under-recruited.

    In plain wordsAcross obesity medication trials including orforglipron, participants aged 40 years or older were over-recruited, while older participants were under-recruited.

    Peptide
    Orforglipron
    Outcome
    MixedAge representation
    Study

    n = 139,566

    Outcome group
    Patterns of use · Whole body

    Source sentences

    Summary
    Most trials over-recruited White, female participants aged 40 years or older with class 1 (30·0-34·9 kg/m2) and class 2 (35·0-39·9 kg/m2) obesity;
    2 context sentences
    Summary · context
    older participants, those with class 3 (≥40·0 kg/m2) obesity, non-White participants, and male participants were under-recruited.
    Summary · context
    246 RCTs were included, involving 139 566 participants with or without type 2 diabetes.

    In this study, Orforglipron was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Orforglipron.

  3. 03HumanNot a test of Orforglipron aloneSystematic reviewOther

    Across obesity medication trials including orforglipron, most trials over-recruited participants with class 1 and class 2 obesity and under-recruited class 3 obesity.

    In plain wordsAcross obesity medication trials including orforglipron, class 1 and class 2 obesity were over-recruited, while class 3 obesity was under-recruited.

    Peptide
    Orforglipron
    Outcome
    MixedObesity severity representation
    Study

    n = 139,566

    Outcome group
    Patterns of use · Whole body

    Source sentences

    Summary
    Most trials over-recruited White, female participants aged 40 years or older with class 1 (30·0-34·9 kg/m2) and class 2 (35·0-39·9 kg/m2) obesity;
    2 context sentences
    Summary · context
    older participants, those with class 3 (≥40·0 kg/m2) obesity, non-White participants, and male participants were under-recruited.
    Summary · context
    246 RCTs were included, involving 139 566 participants with or without type 2 diabetes.

    In this study, Orforglipron was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Orforglipron.

  4. 04HumanNot a test of Semaglutide aloneSystematic reviewOther

    In a systematic review of obesity medication trials including semaglutide, participants were mostly White, female, aged 40 or older with class 1 or 2 obesity; other groups were under-recruited.

    In plain wordsTrials of obesity medicines mostly enrolled White women over 40 with lower obesity classes; other groups were under-represented.

    Peptide
    Semaglutide
    Outcome
    Not applicableRepresentation of sex, race and BMI classes in obesity medication trials
    Study

    n: not reported in source

    Outcome group
    Patterns of use · Whole body

    Source sentences

    Summary
    Most trials over-recruited White, female participants aged 40 years or older with class 1 (30·0-34·9 kg/m2) and class 2 (35·0-39·9 kg/m2) obesity; older participants, those with class 3 (≥40·0 kg/m2) obesity, non-White participants, and male participants were under-recruited.
    1 context sentence
    Summary · context
    246 RCTs were included, involving 139 566 participants with or without type 2 diabetes.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  5. 05HumanNot a test of Liraglutide aloneSystematic reviewOther

    In a systematic review of obesity medication trials including liraglutide, participants were mostly White, female, aged 40 or older with class 1 or 2 obesity; other groups were under-recruited.

    In plain wordsTrials of obesity medicines mostly enrolled White women over 40 with lower obesity classes; other groups were under-represented.

    Peptide
    Liraglutide
    Outcome
    Not applicableRepresentation of sex, race and BMI classes in obesity medication trials
    Study

    n: not reported in source

    Outcome group
    Patterns of use · Whole body

    Source sentences

    Summary
    Most trials over-recruited White, female participants aged 40 years or older with class 1 (30·0-34·9 kg/m2) and class 2 (35·0-39·9 kg/m2) obesity; older participants, those with class 3 (≥40·0 kg/m2) obesity, non-White participants, and male participants were under-recruited.
    1 context sentence
    Summary · context
    246 RCTs were included, involving 139 566 participants with or without type 2 diabetes.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 06HumanNot a test of Tirzepatide aloneSystematic reviewOther

    In a systematic review of obesity medication trials including tirzepatide, participants were mostly White, female, aged 40 or older with class 1 or 2 obesity; other groups were under-recruited.

    In plain wordsTrials of obesity medicines mostly enrolled White women over 40 with lower obesity classes; other groups were under-represented.

    Peptide
    Tirzepatide
    Outcome
    Not applicableRepresentation of sex, race and BMI classes in obesity medication trials
    Study

    n: not reported in source

    Outcome group
    Patterns of use · Whole body

    Source sentences

    Summary
    Most trials over-recruited White, female participants aged 40 years or older with class 1 (30·0-34·9 kg/m2) and class 2 (35·0-39·9 kg/m2) obesity; older participants, those with class 3 (≥40·0 kg/m2) obesity, non-White participants, and male participants were under-recruited.
    1 context sentence
    Summary · context
    246 RCTs were included, involving 139 566 participants with or without type 2 diabetes.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 30 to 47Current

    28 Oct 2026, 02:04 UTC

    The same notice was added 18 times, first on 14 Oct 2026, 05:01 UTC. The status did not change between them.

    Study results updated

  2. Version 29

    14 Oct 2026, 01:46 UTC

    Study data updated · source update from Europe PMC

  3. Versions 5 to 28

    13 Oct 2026, 21:46 UTC

    The same notice was added 24 times, first on 9 Oct 2026, 19:08 UTC. The status did not change between them.

    Study results updated

  4. Versions 2 to 4

    9 Oct 2026, 03:07 UTC

    The same notice was added 3 times, first on 9 Oct 2026, 03:05 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  5. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.